What Enal Drugs does

Enal Drugs Private Limited is a Hyderabad-based, ISO 9001:2015 certified pharmaceutical manufacturer specializing in active pharmaceutical ingredients (APIs) and drug intermediates. Founded in 1996 by first-generation entrepreneurs, the company is anchored in anti-ulcerative drugs — particularly proton pump inhibitors (PPIs) such as Lansoprazole, Omeprazole/Esomeprazole, Rabeprazole, and Dexlansoprazole — but has extended its intermediate portfolio into adjacent therapeutic areas including HIV (Dolutegravir), type 2 diabetes (Empagliflozin), anticoagulants (Edoxaban), oncology (Imatinib, Rucaparib), antifungals (Luliconazole), osteoporosis (Risedronate Sodium), and CNS (Zaleplon, Paroxetine). The company operates a single manufacturing site at Jeedimetla, Hyderabad, comprising an Intermediate Block for drug intermediates and a Pharma Block (API Block) with cGMP-grade environmental controls (0.3-micron filtration, 25°C, below 60% relative humidity), equipped with stainless steel and glass-lined reactors, centrifuges, rotary cone vacuum dryers, and QC/QA infrastructure led by a Ph.D in organic chemistry.

The business model is B2B and export-oriented: Enal Drugs sells APIs and intermediates directly to pharmaceutical manufacturers in Europe, Asia, Africa, and South America, with no disclosed branded retail products. Pricing is quote-based and not publicly disclosed, consistent with negotiated bulk-API and intermediate supply contracts. Go-to-market is direct field sales from the Hyderabad site, supplemented by a company website with downloadable product e-brochures. The company holds ISO 9001:2015 certification, has 501-1,000 employees, and is privately held with no disclosed institutional investors, parent company, or external funding rounds. Customer logos, revenue figures, and ownership details beyond the first-generation promoter narrative are not publicly available, and the company has not pursued M&A, partnerships, or a public listing.

Name

Enal Drugs

Legal name

Enal Drugs Private Limited

Website

https://enaldrugs.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Enal Drugs Private Limited is a Hyderabad-based, ISO 9001:2015 certified manufacturer of active pharmaceutical ingredients and drug intermediates, specializing in anti-ulcerative proton pump inhibitors and exporting to pharmaceutical companies across Europe, Asia, Africa, and South America.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Pharmaceutical API manufacturing
• Active pharmaceutical ingredients
• Drug intermediates
• Anti-ulcerative drug manufacturer
• Bulk drug production

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Active Pharmaceutical Ingredients (APIs): Manufacturing and sale of anti-ulcerative drugs including Lansoprazole, Rabeprazole Sodium, Betahistine Di Hydrochloride, Paroxetine Hydrochloride, Dexlansoprazole, Esomeprazole Magnesium, Levosulsupride, and Risedronate Sodium.
2. Drug Intermediates: Production and supply of drug intermediates for various pharmaceutical compounds including Zaleplon, Lansoprazole, Omeprazole/Esomeprazole, Rabeprazole, Flecainide, Luliconazole, Edoxaban, Empagliflozin, Dolutegravir, Imatinib, Rucaparib, Febuxostat, Entacapone, Tolterodine, and Risedronate Sodium.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Enal Drugs Private Limited manufactures Active Pharmaceutical Ingredients (APIs) and drug intermediates, with a specialization in anti-ulcerative drugs (proton pump inhibitors such as Lansoprazole, Rabeprazole, Esomeprazole, Dexlansoprazole) and adjacent therapeutic compounds (Betahistine, Paroxetine, Levosulpride, Risedronate Sodium). The company produces a wide range of drug intermediates for APIs including Lansoprazole, Omeprazole/Esomeprazole, Rabeprazole, Zaleplon, Flecainide, Luliconazole, Edoxaban, Empagliflozin, Dolutegravir, Imatinib, Rucaparib, Febuxostat, Entacapone, Tolterodine, and Risedronate Sodium, supplying pharmaceutical manufacturers globally.

Product overview

Enal Drugs Private Limited is a pharmaceutical manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and drug intermediates. The company operates as a single unified product portfolio comprising two main categories: (1) Active Pharmaceutical Ingredients including Lansoprazole, Rabeprazole Sodium, Betahistine Di Hydrochloride/Mesilate, Paroxetine Hydrochloride/Mesylate, Dexlansoprazole, Esomeprazole Magnesium (Trihydrate and Dihydrate), Levosulpride, and Risedronate Sodium for bone health; and (2) Drug Intermediates covering proton pump inhibitor intermediates (Lansoprazole, Omeprazole/Esomeprazole, Rabeprazole), Zaleplon, Flecainide, Luliconazole, Edoxaban, Empagliflozin, Dolutegravir (multiple intermediates including for Rucaparib and Imatinib combinations), Febuxostat, Tolterodine, Entacapone, and Risedronate Sodium. The company exports to Europe, Asia, Africa, and South American countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (Anti-Ulceratives / PPIs and related) Manufacture and supply of a portfolio of APIs including proton pump inhibitors (Lansoprazole, Rabeprazole Sodium, Dexlansoprazole, Esomeprazole Magnesium Trihydrate/Dihydrate), Levosulpride, and Betahistine Di Hydrochloride/Mesilate, all targeted at pharmaceutical formulators producing finished dosage forms. Products comply with multiple pharmacopoeia standards including USP, EP, BP, JP, and IP.
• Risedronate Sodium API (Bone Resorption Inhibitor) Manufacture and supply of Risedronate Sodium API, a bisphosphonate used by pharmaceutical formulators in finished products for treating and preventing osteoporosis and related bone disorders.
• Lansoprazole Intermediates Supply of key synthesis intermediates for Lansoprazole including 4-Nitro-2,3-dimethylpyridine-N-oxide, 2-Hydroxymethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine hydrochloride, 2-Chloromethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine hydrochloride, and the sulfide-benzimidazole intermediate, targeted at API manufacturers.
• Omeprazole / Esomeprazole Intermediates Supply of intermediates including 2-Chloromethyl-3,5-dimethyl-4-methoxy pyridine hydrochloride and 5-Methoxy-2-({(4-methoxy-3,5-dimethylpyridin-2-yl)methyl}thio)-1H-benzimidazole (Ufiprazole) for omeprazole and esomeprazole API manufacturing.
• Rabeprazole Intermediates Supply of synthesis intermediates including Pyridine-4-chloro-2,3-dimethyl-1-oxide, Pyridine 2-(chloromethyl)-4-(3-methoxy propoxy)-3-methyl hydrochloride, and 2-({4-(3-Methoxypropoxy)-3-methylpyridinyl}methyl)thio-1H-benzimidazole for rabeprazole API manufacturing.
• Zaleplon Intermediates Supply of the key 3-Aminopyrazole-4-carbonitrile intermediate used in the synthesis of Zaleplon, a non-benzodiazepine hypnotic API targeting insomnia treatments.
• Flecainide Intermediate Supply of 2,5-Bis(2,2,2-trifluoroethoxy)benzoic acid intermediate used in the synthesis of Flecainide, an antiarrhythmic agent.
• Luliconazole Intermediate Supply of 1-(Cyanomethyl)imidazole intermediate used in the synthesis of Luliconazole, an antifungal agent for skin infection treatments.
• Edoxaban Intermediate Supply of Ethyl Oxalyl Chloride intermediate used in the synthesis of Edoxaban, an anticoagulant API for blood clot prevention.
• Empagliflozin Intermediate Supply of 2-Chloro-5-bromobenzoic acid intermediate used in the synthesis of Empagliflozin, an SGLT2 inhibitor API for type 2 diabetes treatments.
• Dolutegravir Intermediates Supply of intermediates used in the synthesis of Dolutegravir, an HIV integrase strand transfer inhibitor API for HIV treatment, including 1-(2,2-Dimethoxyethyl)-5-methoxy-6-(methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid and related compounds.
• Febuxostat Intermediate Supply of Ethyl-2-chloroacetoacetate intermediate used in the synthesis of Febuxostat, a xanthine oxidase inhibitor API for gout treatment.
• Tolterodine Intermediate Supply of 3,4-Dihydro-6-methyl-4-phenyl coumarine intermediate used in the synthesis of Tolterodine, an overactive bladder treatment API.
• Entacapone Intermediates Supply of Entacapone synthesis intermediates including 3,4-Dihydroxy-5-nitro benzaldehyde and N,N-Diethyl-2-cyanoacetamide, used in the manufacture of Entacapone, an anti-parkinsonian API used in Parkinson's disease treatment.
• Risedronate Sodium Intermediates Supply of synthesis intermediates used in the production of Risedronate Sodium, a bisphosphonate API used in finished formulations for osteoporosis and Paget's disease treatment.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• MSN Laboratories: Indian API and intermediate manufacturer with a portfolio spanning PPIs, ARVs, oncology, and diabetes APIs/intermediates — closely mirroring Enal's diversified product mix including Dolutegravir and oncology intermediates.
• Natco Pharma: Indian pharma company with a meaningful API and intermediates business alongside finished generics. Overlaps with Enal in PPI and specialty intermediates, exporting globally to formulation companies.
• Dr. Reddy's Laboratories: Indian pharma major with integrated API and intermediates manufacturing, including PPI APIs. Comparable in being a Hyderabad-headquartered, export-driven API/generics business targeting global pharmaceutical customers.
• Aether Industries: Indian intermediates and API manufacturer focused on process development and contract manufacturing. Comparable mid-sized private/listed player competing on similar intermediates (PPI, ARV, oncology) and core technology (multi-reactor facilities, R&D-led scale-up).
• Aurobindo Pharma: One of India's largest API and generic finished-dose manufacturers with substantial PPI (omeprazole, esomeprazole, lansoprazole) and intermediate exposure. Competes with Enal in PPI and broader API markets across regulated and emerging markets.
• Hikal Limited: Indian fine chemicals and API/intermediate manufacturer supplying global pharmaceutical customers, with overlapping product categories including PPI-related intermediates and chronic-disease molecules.
• Shilpa Medicare: Indian API and intermediates producer with active pharmaceutical ingredient manufacturing for proton pump inhibitors and other categories. Similar export-driven B2B model supplying global formulation companies.
• Hetero Labs: Large privately-held Indian API manufacturer particularly strong in PPIs, ARVs (Dolutegravir) and intermediates. Direct overlap with Enal's PPI API and Dolutegravir intermediate portfolios, often competing on the same customer RFPs.

Broad incumbents

• Cipla: Indian pharma major with API manufacturing capability supplying both domestic and export markets. Although predominantly a finished-dose company, its API division overlaps with Enal's PPI and specialty intermediate categories.
• Sun Pharmaceutical Industries: Largest Indian pharma company with broad API and finished-dose operations including GI/PPI categories. Operates in the same end-markets as Enal but at vastly greater scale and with a much wider therapeutic and geography footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/enaldrugs

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enal Drugs